“Global Inflammatory Bowel Diseases (IBD) Drug Market is estimated to reach $8.6bn by 2024” says new Visiongain report

21 June 2019
Pharma

Visiongain has launched a new pharma report Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2019-2029: Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Crohn’s Disease, Ulcerative Colitis, Hospital Pharmacy, Online Pharmacy, Retail Pharmacy.

IBD incidence and prevalence is evolving worldwide and is now anticipated to be an emerging global disease. The inflammatory bowel diseases (IBD) drug market will continue to be driven by rising disease incidence and more-effective non-invasive diagnosis.

The lead analyst of the report commented "Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis. Economic development of newly industrialized countries is expected to intensify, and several developing countries will make the transition to the status of newly industrialized countries. The magnitude of the growth of IBD in newly industrialized countries will depend on several factors, including exposure to relevant environmental risk factors, urbanization of the population, access to health care, the speed of adoption of medical technologies such as colonoscopy, and natural population growth. Advances in electronic surveillance of diseases will also enhance reporting of IBD from many regions that currently lack data."

Leading companies featured in the report include AbbVie, Allergan, Biogen, Celgene Corporation, Gilead Sciences, Janssen, Novartis, Pfizer, Roche, Takeda, UCB Pharma S.A. and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read